Topical Tendinopathy Treatment Phase II Trial

Posted In

Research News

by Laurie Erickson.


Research abstract and photos of two lead authors from Perelman School of Medicine.

Cell Therapy Ltd, now known as Celixir, announced positive phase 2 clinical trial results of Tendoncel®, a topical regenerative treatment for chronic tendon injury.

The press release quoted Dr. Sabena Sultan, Director of Research and Development, of Cell Therapy Ltd:

“Patients using the non-invasive Tendoncel® topical gel for 21 days experienced a clinically relevant and statistically significant improvement in their tendon injury. Reporting an average improvement of 70% on the DASH disability scale and 74% improvement on the PRTEE scale, Tendoncel’s results exceed those expected of injectable treatments and have the advantage of painless topical application.”

Tendoncel contains platelet growth factors, including PDGF-BB, VEGF, PDGF-AA, thrombospondin and angiopoietin.